FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay March 01, 2021 08:30 ET | Source: Fluidigm Corporation Fluidigm Corporation Collaboration Agreement to Market Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase, Sample Collection, and Secure Delivery of Test Results SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the AZOVA™ COVID-19 Test Collection Kit for use with the Fluidigm® Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the company’s Biomark™ HD platform.